Conatus (CNAT), Galmed (GLMD), Intercept (ICPT) Could Be Given Similar Considerations for their Assets - FBR
- Top 10 News for 9/26 - 9/30: Deutsche Bank Soars on Settlement; Twitter Back in the M&A Fray; Nike 'Just Didn't Do It' in Q1
- Wall Street rallies, led by Deutsche Bank, financials
- Viacom (VIAB) Forms Special Committee; Will Explore Potential Combination with CBS (CBS)
- Deutsche Bank (DB) Said Near $5.4B Settlement with U.S. - AFP
- Oil up second straight month on OPEC-fueled rally
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
FBR Capital analyst Vernon Bernardino weighed in on the NASH space after Allergan (NASDAQ: AGN) agreed to acquire Tobira Therapeutics (NASDAQ: TBRA) for a 500% up-front payment and up to $49.84 per share in Contingent Value Rights (CVRs)
Bernardino commented, "While the acquisition premium (500% premium over yesterday's closing price of $4.74/share for TBRA) is outsized even in biotech terms, we think the drug development landscape in NASH, which has been estimated to have $40 billion in market potential, has no approved drugs and is comprised of less than a half dozen drug candidates in the Phase II stage of development. We think companies under our coverage that could be given similar consideration include Conatus Pharmaceuticals (NASDAQ: CNAT), and Galmed Pharmaceuticals (NASDAQ: GLMD), as well as Intercept Pharmaceuticals (NASDAQ: ICPT), which along with Genfit , are the only ones in the Phase III stage of development."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lexmark (LXK) Gets CFIUS Approval for Apex Tech Deal
- DTI Completes Acquisition of EPIQ Systems (EPIQ)
- New York REIT (NYRT) Issues Response to WW Investors; Says Fund Continuing to 'Mislead' Shareholders Regarding Facts
Create E-mail Alert Related CategoriesAnalyst Comments, Rumors
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!